AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 115 filers reported holding AKERO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,686 | +32.9% | 33,331 | +22.7% | 0.00% | 0.0% |
Q2 2023 | $1,269 | +19.8% | 27,172 | -1.8% | 0.00% | +100.0% |
Q1 2023 | $1,059 | -40.8% | 27,682 | -15.2% | 0.00% | -50.0% |
Q4 2022 | $1,788 | -99.7% | 32,629 | +61.2% | 0.00% | +100.0% |
Q3 2022 | $689,000 | +300.6% | 20,237 | +11.3% | 0.00% | – |
Q2 2022 | $172,000 | -33.6% | 18,182 | -0.2% | 0.00% | – |
Q1 2022 | $259,000 | -32.7% | 18,222 | +0.1% | 0.00% | – |
Q4 2021 | $385,000 | -5.6% | 18,197 | -0.4% | 0.00% | – |
Q3 2021 | $408,000 | -25.5% | 18,266 | -17.4% | 0.00% | -100.0% |
Q2 2021 | $548,000 | +40.9% | 22,104 | +65.0% | 0.00% | – |
Q1 2021 | $389,000 | +12.4% | 13,400 | 0.0% | 0.00% | – |
Q4 2020 | $346,000 | +11.3% | 13,400 | +32.7% | 0.00% | – |
Q3 2020 | $311,000 | +23.4% | 10,100 | 0.0% | 0.00% | – |
Q2 2020 | $252,000 | +125.0% | 10,100 | +90.6% | 0.00% | – |
Q1 2020 | $112,000 | -5.1% | 5,300 | 0.0% | 0.00% | – |
Q4 2019 | $118,000 | -2.5% | 5,300 | 0.0% | 0.00% | – |
Q3 2019 | $121,000 | – | 5,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |